pharmaphorum
JUNE 1, 2022
The technology behind virtual reality is rapidly advancing, allowing developers to create entire 3D hospitals for training purposes. In this article, Ben Hargreaves looks at how VR headsets are being used to better educate both healthcare professionals and the general public. Digital healthcare solutions are being talked about with increasing frequency.
Outsourcing Pharma
JUNE 1, 2022
Lithuaniaâs life sciences industry is growing at one of the fastest rates in Europe. Ahead of BIO, Innovation Agency Lithuania explains what the countryâs plans are for future growth in the area and how this is built upon students heading into STEM studies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 1, 2022
GlaxoSmithKline is due to complete the split from its consumer health decision – now renamed Haleon – next month, with a listing for the new company on the London Stock Exchange set for 18 July. GSK said it has now filed a prospectus for the submission of Haleon’s ordinary shares to the stock market with the Financial Conduct Authority (FCA), and is awaiting approval for the move.
Outsourcing Pharma
JUNE 1, 2022
The Lifebit CloudOS will be employed to create a Federate Trusted Research Environment within the centerâs supercomputing cluster to handle data management.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
JUNE 1, 2022
Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two glycoprotein targets. The Japanese drugmaker is paying $20.5 million upfront to get the ball rolling, while milestone and other payments could take the total value of the deal up to $783.5 million.
Outsourcing Pharma
JUNE 1, 2022
A Touch, the Black Breast Cancer Alliance leader discusses how a grant from Genentech is helping the organization break down barriers in care and research.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Roots Analysis
JUNE 1, 2022
Over the past decade, the field of synthetic biology has witnessed several advancements. DNA cloning is the field of synthetic biology which can be helpful to understand the effect of mutation on a particular gene. Many diseases that can be treated using DNA cloning, such as leukemia and sickle cell anemia, involving the replacement of defected gene.
pharmaphorum
JUNE 1, 2022
For the first time since 2019, the American Society of Clinical Oncology (ASCO) annual meeting will be an in-person conference. We’re excited to re-connect with fellow oncology and clinical care professionals from across the globe to learn from one another and discuss key advances in cancer care and research. From innovations in cancer therapeutics to developments in genetic testing and biomarkers to the role of data analytics and technologies in oncology trials, insightful conversations can cre
Med Ed 101
JUNE 1, 2022
Though antipsychotics are generally used for long-term treatment of psychiatric conditions, there are several instances where therapy may be stopped altogether. We outline several practice pearls and clinical considerations when determining if antipsychotic tapering is appropriate. Deprescribing antipsychotic therapy may be appropriate in a number of different situations as listed below.
pharmaphorum
JUNE 1, 2022
To improve outcomes for cancer patients and take advantage of the ground-breaking scientific and technological progress made in oncology prevention, diagnosis, therapy and care over recent years, it is of crucial importance to ensure all patients with cancer have an ongoing dialogue with the healthcare team. However, over the last years the COVID-19 pandemic has interrupted that dialogue in many places.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
JUNE 1, 2022
The drug is used to treat seizures caused by this rare syndrome that is a form of epilepsy
pharmaphorum
JUNE 1, 2022
Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just reported phase 2 trial results with the small, interfering RNA (siRNA) gene-silencing drug showing that it an cause a 90% or greater reduction in Lp(a) levels – a risk factor for cardiovascular disease – that was sustained over 48 weeks of follow-up.
Pharma Times
JUNE 1, 2022
Apixaban will be available for the prevention of stroke and deep vein thrombosis
Expert insights. Personalized for you.
145 
Let's personalize your content